

Amendment to the Claims

Please cancel claims 3-6 and 14-20. Please amend claims 7-10, 12 and 23-27 as follows:

1. (Original) A pharmaceutical composition comprising:
 - a pharmaceutically acceptable carrier or diluent; and,
 - one or more compounds having a structure selected from the group consisting of mifepristone, Formulas D1-D20, and pharmaceutically acceptable salts thereof;
 - wherein said compound is present in an amount effective to inhibit HIV in an individual, said composition being in the form selected from the group consisting of:
 - a composition formulated as a transdermal patch;
 - a composition formulated as a subdermal delivery system; and
 - a controlled/sustained release formulation.
2. (Original) The pharmaceutical composition of claim 1 further comprising one or more compounds having a structure selected from the group consisting: zidovudine (AZT), abacavir, 3TC, d4T, ddI, ddC, efavirenz, nevirapine, delavirdine, amprenavir, Indinavir, Lopinavir, nelfinavir, ritonavir, saquinavir, acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b.
- Claims 3 - 6. (Canceled)
7. (Currently amended) The pharmaceutical composition of ~~any~~ of claims 1 ~~to 5~~ wherein said composition comprises 10-120 mg mifepristone.
8. (Currently amended) The pharmaceutical composition of ~~any~~ of claims 1 ~~to 5~~ wherein said composition comprises 60 mg mifepristone.

9. (Currently amended) The pharmaceutical composition of ~~any of claims 1 to 5~~ wherein said composition comprises 30 mg mifepristone.

10. (Currently amended) A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to ~~any one of claims 1-9~~.

11. (Original) The method of claim 10 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

12. (Currently amended) A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to claims 1-9.

13. (Original) A method of claim 12 wherein said individual is administered mifepristone at a dosage level to achieve steady-state serum drug concentration of 17-430 ng/ml.

Claims 14 - 20. (Canceled)

21. (Original) A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and, one or more compounds having a structure selected from the group consisting of: hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite, Compounds D1- D20, and pharmaceutically acceptable salts thereof; wherein said compound is present in an amount effective to inhibit HIV in an individual.

22. (Original) The pharmaceutical composition of claim 21 further comprising one or more compounds having a structure selected from the group consisting: mifepristone, zidovudine (AZT), abacavir, 3TC, d4T, ddl, ddC, efavirenz, nevirapine, delavidine, amprenavir, Indinavir, Lopinavir, nelfinavir, ritonavir, sanquinavir, acyclovir, ganciclovir, foscarnet, interferon alpha-2a, and interferon alpha-2b

23. (Currently amended) The pharmaceutical composition of ~~any one of~~ claims 21-22 comprising 10-120 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite, a pharmaceutically acceptable salt thereof or a combination thereof.

24. (Currently amended) The pharmaceutical composition of ~~any one of~~ claims 21-23 wherein said composition comprises 60 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite a pharmaceutically acceptable salt thereof or a combination thereof.

25. (Currently amended) The pharmaceutical composition of ~~any of any one of~~ claims 21-24 wherein said composition comprises 30 mg hydroxylated mifepristone metabolite, monodemethylated mifepristone metabolite, didemethylated mifepristone metabolite a pharmaceutically acceptable salt thereof or a combination thereof.. .

26. (Currently amended) A method of treating an individual who is infected with HIV comprising the step of administering to said individual a therapeutically effective amount of a composition according to ~~any one of~~ claims 21-25.

27. (Currently amended) A method of preventing HIV infection in an individual identified as being a high risk individual, the method comprising the step of administering to said individual a prophylactically effective amount of a composition according to ~~any one of~~ claims 21-26.